Ulrich Hassiepen
Novartis (Switzerland)(CH)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Peptidase Inhibition and Analysis, Protein Degradation and Inhibitors, Diabetes Treatment and Management, Neuropeptides and Animal Physiology
Most-Cited Works
- → Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide(2014)1,049 cited
- → Crystal structure of the human COP9 signalosome(2014)226 cited
- → Structural Basis of Ubiquitin Recognition by the Deubiquitinating Protease USP2(2006)214 cited
- → Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome(2016)211 cited
- → Targeted inhibition of the COP9 signalosome for treatment of cancer(2016)197 cited
- → Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions(2014)146 cited
- → MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans(2019)120 cited
- → Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited(2008)111 cited
- → A sensitive fluorescence intensity assay for deubiquitinating proteases using ubiquitin-rhodamine110-glycine as substrate(2007)110 cited
- → Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation(2019)78 cited